Valuation: Royalty Pharma plc

Market Cap 26.08B 22.9B 21.3B 19.55B 36.73B 2,511B 37.29B 253B 98.82B 1,235B 97.9B 95.79B 4,269B P/E 2026 *
22.2x
P/E 2027 * 15.5x
Enterprise Value 35.23B 30.94B 28.78B 26.41B 49.62B 3,393B 50.38B 342B 134B 1,668B 132B 129B 5,767B EV / Sales 2026 *
10.2x
EV / Sales 2027 * 9.55x
Free-Float
71.97%
Yield 2026 *
1.7%
Yield 2027 * 1.79%
1 day-0.32%
1 week+1.12%
Current month+4.92%
1 month+7.57%
3 months+19.14%
6 months+45.62%
Current year+52.25%
1 week 56.9
Extreme 56.9
59.72
1 month 54.95
Extreme 54.95
59.72
Current year 38.29
Extreme 38.29
59.72
1 year 34.08
Extreme 34.0805
59.72
3 years 24.05
Extreme 24.05
59.72
5 years 24.05
Extreme 24.05
59.72
10 years 24.05
Extreme 24.05
59.72
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Executive/Senior Manager

-9,099 0.0021%
6/30/26 Sell

Executive/Senior Manager

-130,000 0.0293%
6/30/26 Free

Director

689 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.32%+1.12%+60.43%+88.56% 26.08B
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
+1.60%+6.25%+37.00%+30.00% 347B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
Average +0.41%+1.31%+29.62%+55.98% 366.96B
Weighted average by Cap. +0.76%+1.95%+36.17%+78.22%

Financials

2026 *2027 *
Net sales 3.47B 3.05B 2.83B 2.6B 4.89B 334B 4.96B 33.65B 13.15B 164B 13.02B 12.74B 568B 3.71B 3.25B 3.03B 2.78B 5.22B 357B 5.3B 35.95B 14.04B 175B 13.91B 13.61B 607B
Net income 1.65B 1.45B 1.35B 1.24B 2.33B 159B 2.37B 16.04B 6.27B 78.3B 6.21B 6.07B 271B 2.24B 1.96B 1.83B 1.68B 3.15B 215B 3.2B 21.7B 8.48B 106B 8.4B 8.22B 366B
Net Debt 9.15B 8.04B 7.48B 6.86B 12.89B 881B 13.09B 88.78B 34.69B 433B 34.36B 33.62B 1,498B 9.33B 8.19B 7.62B 6.99B 13.13B 898B 13.33B 90.45B 35.34B 441B 35.01B 34.25B 1,526B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
26-07-24 US$58.83 -0.32% 2,114,330
26-07-23 US$59.02 +0.51% 2,159,891
26-07-22 US$58.72 +0.51% 2,618,886
26-07-21 US$58.42 +1.96% 3,716,803
26-07-20 US$57.30 -1.52% 3,245,529
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
58.83USD
Average target price
59.89USD
Spread / Average Target
+1.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock